Form 4: Day One Biopharmaceuticals Acquired by Servier

Director Saira Ramasastry reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Summary

• Day One Biopharmaceuticals, Inc. has been acquired by Servier Pharmaceuticals LLC.
• The merger was finalized on April 23, 2026.
• All outstanding common stock was converted into the right to receive $21.50 per share in cash.
• All outstanding stock options and restricted stock units (RSUs) were fully vested immediately prior to the merger and converted into cash payments based on the merger consideration.
• Reporting person Saira Ramasastry disposed of 40,485 shares of common stock and various derivative securities as part of the transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative filing for a company that has been successfully acquired.

Positives

• Shareholders received a cash consideration of $21.50 per share.
• All unvested equity awards were accelerated and fully vested upon the closing of the merger.

Negatives

• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Servier.

Risks

• The company has ceased to exist as an independent public entity, eliminating future investment opportunities in the stock.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; therefore, no further public guidance or forward-looking statements will be provided by the issuer.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The acquisition price of $21.50 per share represents a standard exit strategy for clinical-stage biopharmaceutical companies.
• The acceleration of unvested equity is a standard provision in change-of-control agreements within the biotech sector.

Stakeholder Impact

• Shareholders receive cash proceeds for their holdings.
• Employees and management transition to the parent company, Servier.

Next Steps

• Delisting of Day One Biopharmaceuticals common stock from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, Servier, Merger, Acquisition, DAWN, Form 4, Biotech